Tag - ITRM

Developments

Iterum Therapeutics reports mixed topline results from Phase 3 sulopenem trial

Iterum Therapeutics (NASDAQ:ITRM) reported mixed topline results from its clinical trial assessing sulopenem, an anti-infective compound, in combination with probenecid for the treatment of uncomplicated urinary tract...

June 29, 2020

Markets

HCW cuts Iterum Therapeutics PT to $9 from $14

H.C. Wainwright lowered its price target for Iterum Therapeutics (NASDAQ:ITRM) to $9 from $14 after the company unveiled a $52-million private placement of exchangeable and royalty-linked subordinated notes earlier this...

January 31, 2020

Tag - ITRM

Iterum Therapeutics reports mixed topline results from Phase 3 sulopenem trial

HCW cuts Iterum Therapeutics PT to $9 from $14

General

More